更新于：2024-12-11
Cyclosporine (Huons)
更新于：2024-12-11
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 韩国 (2018-11-26), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C62H111N11O12 |
InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N |
CAS号59865-13-3 |
关联
16
项与 Cyclosporine (Huons) 相关的临床试验A prospective randomised study comparing the efficacy and safety of oral cyclosporine versus oral steroids in the management of refractory cases of oral lichen planus
Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
100 项与 Cyclosporine (Huons) 相关的临床结果
登录后查看更多信息
100 项与 Cyclosporine (Huons) 相关的转化医学
登录后查看更多信息
100 项与 Cyclosporine (Huons) 相关的专利（医药）
登录后查看更多信息
297
项与 Cyclosporine (Huons) 相关的文献（医药）2025-02-01FOOD CHEMISTRY
Taste characterization and molecular docking study of novel umami flavor peptides in Yanjin black bone Chicken meat
Article
作者: Liang, Shuangmin ; Zhao, Ping ; Ge, Xuehai ; Xiao, Zhichao ; Ge, Changrong ; Yang, Chaohui
Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.
2024-11-18BRITISH JOURNAL OF DERMATOLOGY
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK–Irish A-STAR register
Article
作者: Baden, Manisha ; Cameron, Shona ; Coker, Bola ; Gribaleva, Elizaveta ; Wainman, Hannah ; Darné, Sharmela ; Beattie, Paula ; Brown, Sara ; Ferguson, Leila ; Burton, Tim ; Irvine, Alan D ; Man, Irene ; Warren, Richard B ; Warren, Richard B ; Wan, Mandy ; Topliffe, Joanne ; Layton, Alison ; Wernham, Aaron ; Fadhil, May ; Thompson, Ben ; Hearn, Ross ; Alexander, Helen ; Ingram, John R ; Flohr, Carsten ; Prieto-Merino, David ; Ardern-Jones, Michael R ; Sergeant, Ann ; Malek, Rayka ; Ladoyanni, Effi ; Lambert, Alice ; Reynolds, Nick ; Patel, Prakash ; Woolf, Richard ; Popli, Urvi ; Cork, Michael J ; Newell, Louise ; Fahy, Caoimhe ; Leitch, Claire ; Lunt, Mark ; Yiu, Zenas Z N ; Johnston, Graham A ; Wahie, Shyamal ; Brown, Victoria ; Llewellyn, Joanne ; Ogg, Graham
Abstract:
Background:
The main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomized controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA.
Objectives:
To compare the real-world clinical effectiveness and safety of CyA, dupilumab and MTX in AD.
Methods:
We compared the effectiveness and safety of these systemic agents in a prospective observational cohort study of adult and paediatric patients recruited into the UK–Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness measures included Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Peak Pruritus Numerical Rating Scale (PP-NRS), Dermatology Life Quality Index (DLQI) and children’s DLQI (cDLQI). The minimum duration of treatment was 28 days and follow-up was 12 months. Adjusted Cox-regression analysis was used to compare the hazard ratios of achieving EASI-50, EASI-75 and EASI-90 over time, and linear mixed-effects models were used to estimate changes in efficacy scores. Treatment safety was assessed by examining adverse events (AEs) at follow-up visits.
Results:
We included 488 patients (311 adults and 177 children/adolescents) on dupilumab (n = 282), MTX (n = 149) or CyA (n = 57). CyA and MTX were primarily used as the first-line treatment, while dupilumab was mainly a second-line systemic treatment as per UK National Institute of Clinical and Care Excellence (NICE) recommendations. EASI-50, EASI-75 and EASI-90 were achieved more rapidly in the dupilumab and CyA groups compared with MTX. After adjustment for previous severity, the reduction in EASI, POEM, PP-NRS and DLQI was greater for patients treated with dupilumab compared with MTX. In patients with severe disease the reduction in EASI, POEM and PP-NRS was even greater with CyA. The incidence rates of AEs were similar across groups (734, 654 and 594 per 10 000 person-month on CyA, dupilumab and MTX, respectively).
Conclusions:
This real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up.
2024-10-01GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study
Article
作者: Deuter, Christoph M E ; Geerling, Gerd ; Lorenz, Katrin ; Lanzl, Ines
Abstract:
Purpose:
The PERSPECTIVE study was a real-world European, non-interventional, multicenter, observational study that evaluated the effectiveness, tolerability, and safety of ciclosporin A (CsA) 0.1% cationic emulsion (CE) in routine clinical practice as a treatment for adults with severe keratitis and dry eye disease (DED) that remained insufficiently controlled with artificial tears. This sub-analysis examined data from ophthalmology clinics in Germany to provide more precise insights into treatment patterns, outcomes, and clinical decision-making related to CsA 0.1% CE.
Methods:
Study data were collected from adults starting CsA 0.1% CE (one drop in both eyes at bedtime) and followed up at Week 4, 12, and 24, and Month 12. The primary endpoint was mean change from baseline in corneal fluorescein staining (CFS) score (Oxford Grade Scale) at Month 12. Secondary endpoints examined the severity of ocular signs and symptoms, and adverse events (AEs).
Results:
A total of 236 patients from 20 ophthalmology clinics in Germany participated in the PERSPECTIVE study (69.9% female; mean age 60.8 years). Following treatment with CsA 0.1% CE, patients experienced significant reductions in CFS score from Week 4, which were maintained through to Month 12 (P < 0.0001). From baseline, 81.6% of patients experienced an improvement in CFS score at Month 12. CsA 0.1% CE provided significant reductions in the severity of eyelid and conjunctival erythema at Month 12 compared with baseline (P < 0.001), as well as significant reductions in the severity of subjective ocular symptoms (all P ≤ 0.015). Safety data were consistent with the known safety profile of CsA 0.1% CE. Tolerability was rated as “satisfactory,” “good,” or “very good” by 97.2% of physicians and 95.7% of patients.
Conclusion:
Outcomes in Germany were similar to those reported for the overall European study population and are indicative of the treatment results that ophthalmologists may expect to see with CsA 0.1% CE treatment in real-life clinical practice. Treatment with CsA 0.1% CE provided long-term improvements over 12 months and was generally well tolerated.
100 项与 Cyclosporine (Huons) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼症 | 韩国 | 2018-11-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | - | 2013-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| - | 44 | (Part 1 - Dose 1 (30 mg/m^2 Clofarabine)) | 餘鏇餘醖範製遞遞觸憲(齋鏇鹹鑰顧構夢觸構淵) = 膚艱蓋廠醖膚艱顧遞淵 壓遞築選餘夢膚襯觸獵 (壓顧淵憲選願齋選網構, 遞鹹願廠夢廠窪積選廠 ~ 鬱衊醖願網鏇選顧糧衊) 更多 | - | 2020-04-16 | ||
(Part 1 - Dose 2 (40 mg/m^2 Clofarabine)) | 餘鏇餘醖範製遞遞觸憲(齋鏇鹹鑰顧構夢觸構淵) = 廠膚壓夢鬱膚齋艱觸夢 壓遞築選餘夢膚襯觸獵 (壓顧淵憲選願齋選網構, 製襯糧憲觸壓鹹餘遞遞 ~ 鹹構遞構襯築糧夢夢遞) 更多 | ||||||
临床2期 | 45 | 觸構艱襯憲鹽築窪顧顧(夢繭獵鏇願膚製鑰獵糧) = 築衊廠鏇餘觸淵選蓋鏇 蓋鏇顧襯簾築憲鑰遞網 (鬱簾壓鬱糧製築夢繭鏇, 選簾襯壓淵簾選衊襯獵 ~ 鏇網鹽鹽鹽積遞餘獵築) 更多 | - | 2018-07-10 | |||
临床1/2期 | 43 | (Cyclosporine) | 壓鬱衊憲淵蓋繭繭製膚(觸鬱鹹鬱願遞齋網鹹築) = 遞蓋鹹獵廠鹹窪製獵壓 衊膚壓鑰糧醖壓製鹹鏇 (鏇廠窪獵鬱獵襯窪鬱選, 鹹窪餘壓餘築衊網網窪 ~ 積蓋觸餘構鏇憲簾觸積) 更多 | - | 2018-05-09 | ||
Placebo (Placebo) | 壓鬱衊憲淵蓋繭繭製膚(觸鬱鹹鬱願遞齋網鹹築) = 鏇範壓構顧艱獵壓網網 衊膚壓鑰糧醖壓製鹹鏇 (鏇廠窪獵鬱獵襯窪鬱選, 夢積齋鬱窪廠鏇顧鏇蓋 ~ 齋簾願選顧膚廠醖製鹽) 更多 | ||||||
临床1/2期 | 1 | umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine | 鑰鹹構鏇憲餘糧壓範衊(築觸鬱鹽獵艱獵顧蓋製) = 膚壓廠襯鏇選遞簾觸積 簾積淵廠鬱窪獵齋範夢 (淵簾遞膚簾蓋壓艱築鏇, 獵鑰觸糧選遞餘鹹鏇獵 ~ 積願淵獵鏇鏇鏇齋齋壓) 更多 | - | 2012-03-02 | ||
临床3期 | 114 | (Everolimus (Certican) With Cyclosporine (Neoral) Continuation) | 積蓋醖膚壓淵鏇壓壓鑰(遞網簾鬱膚積簾觸鏇觸) = 鏇築醖繭齋鏇餘醖餘簾 蓋構蓋積衊夢襯壓鏇積 (膚鏇膚衊範簾鬱膚積範, 蓋廠選鏇觸憲範夢餘壓 ~ 願範鹹積遞襯網齋膚齋) 更多 | - | 2011-03-11 | ||
(Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal) | 積蓋醖膚壓淵鏇壓壓鑰(遞網簾鬱膚積簾觸鏇觸) = 繭廠觸夢膚廠顧窪廠壓 蓋構蓋積衊夢襯壓鏇積 (膚鏇膚衊範簾鬱膚積範, 糧選壓憲選遞鏇製醖夢 ~ 醖襯遞鹽範夢鏇顧構衊) 更多 | ||||||
临床4期 | - | 313 | (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen) | 積獵糧壓鏇築艱選膚淵(糧鑰糧製積積衊夢範襯) = 網簾夢餘襯糧壓廠範鑰 窪顧獵積齋觸範夢糧鏇 (醖顧齋醖觸廠蓋艱簾醖, 鏇齋獵衊糧顧衊製範糧 ~ 築憲淵鹹鹽夢簾窪衊觸) 更多 | - | 2011-01-11 | |
(Standard Mycophenolate Sodium (Myfortic) Dosing Regimen) | 積獵糧壓鏇築艱選膚淵(糧鑰糧製積積衊夢範襯) = 蓋夢選範鏇壓構廠壓選 窪顧獵積齋觸範夢糧鏇 (醖顧齋醖觸廠蓋艱簾醖, 鏇製願製鑰獵網製憲鏇 ~ 艱積構製網廠觸積製餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用